Download PDF
Semin Respir Crit Care Med 2013; 34(06): 770-786
DOI: 10.1055/s-0033-1358558
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgical Pathology of Lung Cancer

M. Katayoon Rezaei
1   The George Washington University Medical Center, Department of Pathology, Washington, DC
,
Norris J. Nolan
1   The George Washington University Medical Center, Department of Pathology, Washington, DC
,
Arnold M. Schwartz
1   The George Washington University Medical Center, Department of Pathology, Washington, DC
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

The diagnosis, treatment, and management of lung tumors represent a complex set of decision algorithms and require the cooperation and interaction of a team of experts and support systems. The surgical pathologist, an early, important member of the diagnostic team, uses clinical and radiological evidence to differentiate benign from malignant tumors and renders a unique diagnosis that provides both prognostic and treatment information. Using routine histopathologic criteria, histochemical and immunohistochemical stains, and molecular and genetic testing, surgical pathologists and cytopathologists may distinguish between small cell and other bronchogenic carcinomas, separate adenocarcinomas from squamous cell carcinomas, differentiate between pleural carcinomas and diffuse malignant mesotheliomas, and discriminate among the varieties of neuroendocrine carcinomas. Among adenocarcinomas, the pathological examination stratifies those tumors with absent or minimal central invasive cores that have an excellent prognosis from the more common adenocarcinomas with larger invasive components. These distinctions are necessary based on differences in tumor biology, response to therapy, and prognosis for these different histological types. Histopathologic analysis should attempt to provide a precise diagnosis and limit the usage of the term non–small cell carcinoma. The team approach also enables the optimal use of tumor tissue for diagnostic purposes as well as molecular genetic testing and the discovery of targetable sites for therapeutic management. Though low-stage tumors tend to be initially treated with surgical resection, more advanced stages will be approached with limited tissue acquisition, necessitating a strategy for best practices of scarce tissue resources. The awareness of diagnostic modalities and tissue handling by all members of the team ensures the best patient-centered care.

Keywords

lung cancer - adenocarcinoma - squamous cell carcinoma - small cell carcinoma - large cell carcinoma - neuroendocrine carcinoma - adenoid cystic carcinoma - mucoepidermoid carcinoma - mesothelioma
 

  • References

  • 1 Cagle PT, Allen TC, Dacic S , et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011; 135 (1) 110-116
    PubMedGoogle Scholar
  • 2 Schwartz AM, Henson DE ; American College of Chest Physicians. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3, Suppl): 78S-93S
    CrossrefPubMedGoogle Scholar
  • 3 Schwartz AM, Rezaei MK. Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e251S-e262S
    CrossrefPubMedGoogle Scholar
  • 4 Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC , Eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours, Vol 10. Lyon, France: IARC; 2004
    Google Scholar
  • 5 Travis WD. Pathology of lung cancer. Clin Chest Med 2011; 32 (4) 669-692
    CrossrefPubMedGoogle Scholar
  • 6 Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23 (1) 65-81 , viii
    CrossrefPubMedGoogle Scholar
  • 7 Chamberlain DW, Wenckebach GF, Alexander F, Fraser RS, Kolin A, Newman T. Pathological examination and the reporting of lung cancer specimens. Clin Lung Cancer 2000; 1 (4) 261-268
    CrossrefPubMedGoogle Scholar
  • 8 Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e30S-e39S
    CrossrefPubMedGoogle Scholar
  • 9 Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24 (10) 1348-1359
    CrossrefPubMedGoogle Scholar
  • 10 Sigel CS, Moreira AL, Travis WD , et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011; 6 (11) 1849-1856
    CrossrefPubMedGoogle Scholar
  • 11 Thunnissen E, Kerr KM, Herth FJ , et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012; 76 (1) 1-18
    CrossrefPubMedGoogle Scholar
  • 12 Hasanovic A, Rekhtman N, Sigel CS, Moreira AL. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Pathol Res Int 2011; 2011: 897292
    PubMedGoogle Scholar
  • 13 Rekhtman N, Brandt SM, Sigel CS , et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6 (3) 451-458
    CrossrefPubMedGoogle Scholar
  • 14 Mani H, Zander DS. Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 1. Chest 2012; 142 (5) 1316-1323
    CrossrefPubMedGoogle Scholar
  • 15 Mani H, Zander DS. Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2. Chest 2012; 142 (5) 1324-1333
    CrossrefPubMedGoogle Scholar
  • 16 Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23 (5) 654-661
    CrossrefPubMedGoogle Scholar
  • 17 Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41 (1) 20-25
    CrossrefPubMedGoogle Scholar
  • 18 Bordoni A, Bongiovanni M, Mazzucchelli L, Spitale A. Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study. J Cancer Epidemiol 2011; 2011: 275758 doi:10.1155/2011/275758. Epub 2011 Dec 29
    PubMedGoogle Scholar
  • 19 Ikeda S, Fujimori M, Shibata S , et al. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer 2006; 6: 31
    CrossrefPubMedGoogle Scholar
  • 20 Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131 (10) 1561-1567
    PubMedGoogle Scholar
  • 21 Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27 (8) 1031-1051
    CrossrefPubMedGoogle Scholar
  • 22 Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 2006; 19 (8) 1117-1123
    PubMedGoogle Scholar
  • 23 Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35 (1) 15-25
    CrossrefPubMedGoogle Scholar
  • 24 Ring BZ, Seitz RS, Beck RA , et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009; 22 (8) 1032-1043
    CrossrefPubMedGoogle Scholar
  • 25 Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15 (4) 415-420
    CrossrefPubMedGoogle Scholar
  • 26 Travis WD, Brambilla E, Noguchi M , et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6 (2) 244-285
    CrossrefPubMedGoogle Scholar
  • 27 Travis WD, Brambilla E, Van Schil P , et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011; 38 (2) 239-243
    CrossrefPubMedGoogle Scholar
  • 28 Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010; 116 (3) 659-669
    CrossrefPubMedGoogle Scholar
  • 29 Yoshizawa A, Motoi N, Riely GJ , et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24 (5) 653-664
    CrossrefPubMedGoogle Scholar
  • 30 Thunnissen E, Beasley MB, Borczuk AC , et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: an international interobserver study. Mod Pathol 2012; 25 (12) 1574-1583
    CrossrefPubMedGoogle Scholar
  • 31 Noguchi M, Morikawa A, Kawasaki M , et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75 (12) 2844-2852
    CrossrefPubMedGoogle Scholar
  • 32 Suzuki K, Yokose T, Yoshida J , et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000; 69 (3) 893-897
    CrossrefPubMedGoogle Scholar
  • 33 Van Schil PE, Asamura H, Rusch VW , et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J 2012; 39 (2) 478-486
    CrossrefPubMedGoogle Scholar
  • 34 Borczuk AC. Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol 2012; 25 (Suppl. 01) S1-S10
    CrossrefPubMedGoogle Scholar
  • 35 Girard N, Deshpande C, Lau C , et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33 (12) 1752-1764
    CrossrefPubMedGoogle Scholar
  • 36 Girard N, Ostrovnaya I, Lau C , et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15 (16) 5184-5190
    CrossrefPubMedGoogle Scholar
  • 37 Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34 (12) 1805-1811
    CrossrefPubMedGoogle Scholar
  • 38 Tsuta K, Tanabe Y, Yoshida A , et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol 2011; 6 (7) 1190-1199
    CrossrefPubMedGoogle Scholar
  • 39 Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136 (2) 163-171
    CrossrefPubMedGoogle Scholar
  • 40 Lindeman NI, Cagle PT, Beasley MB , et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15 (4) 415-453
    CrossrefPubMedGoogle Scholar
  • 41 Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med 2012; 136 (5) 504-509
    CrossrefPubMedGoogle Scholar
  • 42 Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 2012; 136 (12) 1482-1491
    CrossrefPubMedGoogle Scholar
  • 43 Maemondo M, Inoue A, Kobayashi K , et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25) 2380-2388
    CrossrefPubMedGoogle Scholar
  • 44 Lynch TJ, Bell DW, Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
    CrossrefPubMedGoogle Scholar
  • 45 Mitsudomi T, Morita S, Yatabe Y , et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2) 121-128
    CrossrefPubMedGoogle Scholar
  • 46 Mok TS, Wu YL, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10) 947-957
    CrossrefPubMedGoogle Scholar
  • 47 Paez JG, Jänne PA, Lee JC , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676) 1497-1500
    CrossrefPubMedGoogle Scholar
  • 48 Shaw AT, Yeap BY, Mino-Kenudson M , et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27 (26) 4247-4253
    CrossrefPubMedGoogle Scholar
  • 49 Gainor JF, Varghese AM, Ou SH , et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19 (15) 4273-4281
    CrossrefPubMedGoogle Scholar
  • 50 Wong DW, Leung EL, So KK , et al; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115 (8) 1723-1733
    CrossrefPubMedGoogle Scholar
  • 51 Kwak EL, Bang YJ, Camidge DR , et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363 (18) 1693-1703
    CrossrefPubMedGoogle Scholar
  • 52 Shaw AT, Kim DW, Nakagawa K , et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedGoogle Scholar
  • 53 Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009; 1795 (1) 37-52
    PubMedGoogle Scholar
  • 54 Yoshida A, Kohno T, Tsuta K , et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013; 37 (4) 554-562
    CrossrefPubMedGoogle Scholar
  • 55 Bergethon K, Shaw AT, Ou SH , et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30 (8) 863-870
    CrossrefPubMedGoogle Scholar
  • 56 Bos M, Gardizi M, Schildhaus HU , et al. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013; 81 (1) 142-143
    CrossrefPubMedGoogle Scholar
  • 57 Funai K, Yokose T, Ishii G , et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 2003; 27 (7) 978-984
    CrossrefPubMedGoogle Scholar
  • 58 Moro-Sibilot D, Lantuejoul S, Diab S , et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008; 31 (4) 854-859
    CrossrefPubMedGoogle Scholar
  • 59 Zhang H, Liu J, Cagle PT, Allen TC, Laga AC, Zander DS. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol 2005; 18 (1) 111-118
    CrossrefPubMedGoogle Scholar
  • 60 Pelosi G, Fabbri A, Bianchi F , et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012; 7 (2) 281-290
    CrossrefPubMedGoogle Scholar
  • 61 Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012; 25 (Suppl. 01) S18-S30
    CrossrefPubMedGoogle Scholar
  • 62 Bishop JA, Ogawa T, Chang X , et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2012; 36 (1) 142-148
    CrossrefPubMedGoogle Scholar
  • 63 Weiss J, Sos ML, Seidel D , et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2 (62) 62ra93
    CrossrefPubMedGoogle Scholar
  • 64 Dutt A, Ramos AH, Hammerman PS , et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011; 6 (6) e20351
    CrossrefPubMedGoogle Scholar
  • 65 Olaso E, Labrador JP, Wang L , et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002; 277 (5) 3606-3613
    CrossrefPubMedGoogle Scholar
  • 66 Hammerman PS, Sos ML, Ramos AH , et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1 (1) 78-89
    CrossrefPubMedGoogle Scholar
  • 67 Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010; 134 (11) 1628-1638
    PubMedGoogle Scholar
  • 68 Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012; 1826 (2) 255-271
    PubMedGoogle Scholar
  • 69 Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20 (1) 1-12
    CrossrefPubMedGoogle Scholar
  • 70 Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113 (1) 5-21
    CrossrefPubMedGoogle Scholar
  • 71 Powell JM. Metastatic carcinoid of bone. Report of two cases and review of the literature. Clin Orthop Relat Res 1988; (230) 266-272
    PubMedGoogle Scholar
  • 72 McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg 1985; 89 (1) 8-17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005; 29 (2) 179-187
    CrossrefPubMedGoogle Scholar
  • 74 Lim E, Goldstraw P, Nicholson AG , et al. Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol 2008; 3 (10) 1194-1201
    CrossrefPubMedGoogle Scholar
  • 75 Travis WD, Giroux DJ, Chansky K , et al; International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3 (11) 1213-1223
    CrossrefPubMedGoogle Scholar
  • 76 Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007; 15 (4) 407-414
    CrossrefPubMedGoogle Scholar
  • 77 Sica G, Wagner PL, Altorki N , et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med 2008; 132 (12) 1889-1895
    PubMedGoogle Scholar
  • 78 den Bakker MA, Thunnissen FB. Neuroendocrine tumours–challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. J Clin Pathol 2013; May 17. [Epub ahead of print]
    PubMedGoogle Scholar
  • 79 Swarts DR, Henfling ME, Van Neste L , et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res 2013; 19 (8) 2197-2207
    CrossrefPubMedGoogle Scholar
  • 80 Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001; 116 (4) 466-472
    CrossrefPubMedGoogle Scholar
  • 81 Vallières E, Shepherd FA, Crowley J , et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4 (9) 1049-1059
    CrossrefPubMedGoogle Scholar
  • 82 Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol 2008; 3 (11) 1267-1271
    CrossrefPubMedGoogle Scholar
  • 83 Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer?. Thorac Surg Clin 2004; 14 (2) 271-281
    CrossrefPubMedGoogle Scholar
  • 84 Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998; 29 (3) 272-279
    CrossrefPubMedGoogle Scholar
  • 85 Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 2007; 84 (2) 702-707
    CrossrefPubMedGoogle Scholar
  • 86 Weissferdt A, Moran CA. Pulmonary salivary gland-type tumors with features of malignant mixed tumor (carcinoma ex pleomorphic adenoma): a clinicopathologic study of five cases. Am J Clin Pathol 2011; 136 (5) 793-798
    CrossrefPubMedGoogle Scholar
  • 87 Moran CA. Primary salivary gland-type tumors of the lung. Semin Diagn Pathol 1995; 12 (2) 106-122
    PubMedGoogle Scholar
  • 88 Molina JR, Aubry MC, Lewis JE , et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer 2007; 110 (10) 2253-2259
    CrossrefPubMedGoogle Scholar
  • 89 Maygarden SJ, Detterbeck FC, Funkhouser WK. Bronchial margins in lung cancer resection specimens: utility of frozen section and gross evaluation. Mod Pathol 2004; 17 (9) 1080-1086
    CrossrefPubMedGoogle Scholar
  • 90 Heitmiller RF, Mathisen DJ, Ferry JA, Mark EJ, Grillo HC. Mucoepidermoid lung tumors. Ann Thorac Surg 1989; 47 (3) 394-399
    CrossrefPubMedGoogle Scholar
  • 91 Yousem SA, Hochholzer L. Mucoepidermoid tumors of the lung. Cancer 1987; 60 (6) 1346-1352
    CrossrefPubMedGoogle Scholar
  • 92 Kang DY, Yoon YS, Kim HK , et al. Primary salivary gland-type lung cancer: surgical outcomes. Lung Cancer 2011; 72 (2) 250-254
    CrossrefPubMedGoogle Scholar
  • 93 Achcar RdeO, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA. Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol 2009; 40 (6) 854-860
    CrossrefPubMedGoogle Scholar
  • 94 Doganay L, Bilgi S, Ozdil A, Yoruk Y, Altaner S, Kutlu K. Epithelial-myoepithelial carcinoma of the lung. A case report and review of the literature. Arch Pathol Lab Med 2003; 127 (4) e177-e180
    PubMedGoogle Scholar
  • 95 Nguyen CV, Suster S, Moran CA. Pulmonary epithelial-myoepithelial carcinoma: a clinicopathologic and immunohistochemical study of 5 cases. Hum Pathol 2009; 40 (3) 366-373
    CrossrefPubMedGoogle Scholar
  • 96 Churg A, Colby TV, Cagle P , et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24 (9) 1183-1200
    CrossrefPubMedGoogle Scholar
  • 97 Bhardwaj R. Differentiation of malignant pleural mesothelioma from other pleural diseases. Thorax 2012; 67 (1) 61
    CrossrefPubMedGoogle Scholar
  • 98 Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 118 (2) 90-96
    CrossrefPubMedGoogle Scholar
  • 99 Butnor KJ, Sporn TA, Ordonez NG ; Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of pleural mesothelioma. Hum Pathol 2007; 38 (11) 1587-1589
    PubMedGoogle Scholar
  • 100 McCaughey WT, Colby TV, Battifora H , et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. Mod Pathol 1991; 4 (3) 342-353
    PubMedGoogle Scholar
  • 101 Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics 1996; 16 (3) 613-644
    PubMedGoogle Scholar
  • 102 Kao SC, Griggs K, Lee K , et al. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology 2011; 43 (4) 313-317
    CrossrefPubMedGoogle Scholar
  • 103 Klebe S, Nurminen M, Leigh J, Henderson DW. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009; 41 (2) 140-148
    CrossrefPubMedGoogle Scholar
  • 104 King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48 (3) 223-232
    CrossrefPubMedGoogle Scholar
  • 105 Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol 2010; 38 (1) 9-14
    PubMedGoogle Scholar
  • 106 Yaziji H, Battifora H, Barry TS , et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19 (4) 514-523
    CrossrefPubMedGoogle Scholar
  • 107 Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008; 132 (3) 397-401
    PubMedGoogle Scholar
  • 108 Sidhu GS. The ultrastructure of malignant epithelial neoplasms of the lung. Pathol Annu 1982; 17 (Pt 1) 235-266
    PubMedGoogle Scholar
  • 109 Dardick I, Al-Jabi M, McCaughey WT, Srigley JR, van Nostrand AW, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol 1984; 7 (2-3) 151-160
    CrossrefPubMedGoogle Scholar
  • 110 Flieder DB. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med 2007; 131 (7) 1016-1026
    PubMedGoogle Scholar
  • 111 Butnor KJ, Vollmer RT, Blaszyk H, Glatz K. Interobserver agreement on what constitutes visceral pleural invasion by non-small cell lung carcinoma: an internet-based assessment of international current practices. Am J Clin Pathol 2007; 128 (4) 638-647
    CrossrefPubMedGoogle Scholar
  • 112 Marchevsky AM. Problems in pathologic staging of lung cancer. Arch Pathol Lab Med 2006; 130 (3) 292-302
    PubMedGoogle Scholar
  • 113 Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136 (1) 260-271
    CrossrefPubMedGoogle Scholar
  • 114 Dacic S. Dilemmas in lung cancer staging. Arch Pathol Lab Med 2012; 136 (10) 1194-1197
    CrossrefPubMedGoogle Scholar
  • 115 Detterbeck FC, Boffa DJ, Tanoue LT, Wilson LD. Details and difficulties regarding the new lung cancer staging system. Chest 2010; 137 (5) 1172-1180
    CrossrefPubMedGoogle Scholar
  • 116 Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e369S-e399S
    CrossrefPubMedGoogle Scholar
  • 117 Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e191S-e210S
    CrossrefPubMedGoogle Scholar